Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BTSA1 is a BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 38.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 556.00 | |
500 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | BTSA1 is a BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. |
Targets&IC50 | Bax:250 nM (IC50), Bax:144 nM (EC50) |
In vitro | BTSA1 has no capacity to directly activate the pro-apoptotic homolog BAK. BTSA1 treatment potently and dose-responsively induces membrane translocation of recombinant soluble BAX to the mitochondrial membrane, which is followed by induction of BAX oligomerization. BTSA1-induced BAX activation promotes apoptosis in cancer cells. BTSA1 reduces the viability of all AML cell lines in a dose-dependent manner with IC50 values ranged between 1 and 4 μM, which leads to complete effect within 24 hr treatment. It induces dose-dependent caspase-3/7 activation in all five AML cell lines[1]. |
In vivo | BTSA1 potently suppresses human acute myeloid leukemia (AML) xenografts and increases host survival without toxicity. It is well-tolerated in mice with no toxic effects on healthy hematopoiesis, including healthy stem cell-enriched (LSK) cells, common myeloid progenitors, granulocyte-monocyte progenitors, and megakaryocyte-erythrocyte progenitors. BTSA1 has a substantial half-life in mouse plasma (T1/2 = 15 hr) and oral bioavailability (%F = 51), while a 10 mg/kg dose reaches sufficient levels (~15 μM) of BTSA1 to induce BAX activation and apoptosis in leukemia cells. Thus, BTSA1 is orally bioavailable with excellent pharmacokinetics, has significant anti-tumor activity in leukemia xenografts by promoting apoptosis, and at therapeutically effective doses it does not show any detectable toxicity in the hematopoietic system or other tissues[1]. |
Molecular Weight | 430.51 |
Formula | C21H14N6OS2 |
CAS No. | 314761-14-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (139.37 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BTSA1 314761-14-3 Apoptosis BCL inhibit FITC-BIM caspase-3/7 translocation BTSA 1 Bcl-2 Family BTSA-1 viability Inhibitor mitochondrial pharmacologically BAX AML SAHBA2 inhibitor